Aetna Throws Support Behind Non-invasive Prenatal Tests for Down Syndrome | GenomeWeb

NEW YORK (GenomeWeb News) – Aetna this week issued a clinical policy bulletin suggesting that it may soon begin covering non-invasive prenatal DNA tests for Down syndrome.

In its bulletin, the health insurer said that it "considers measurement of cell-free nucleic acids in maternal blood … medically necessary for testing for fetal aneuploidy (trisomy 13, 18, 21) in pregnant women with single gestations," who meet any one of a set of criteria.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.